Loading
Anyone having cancer treatment who feels unwell, with or without a high temperature, should ring their 24-hour cancer line and be seen in hospital straight away. There they should be given a strong antibiotic through a drip within about an hour, without waiting for the blood count to come back.
Suspect neutropenic sepsis in any adult having anticancer treatment who becomes unwell (NICE CG151 1.3.1.1); NICE NG253 widens this to systemic anticancer treatment within the last 30 days and to people on immunosuppressants, and warns that people having treatment for cancer may not develop a raised temperature. NICE confirms the diagnosis later, at a neutrophil count of 0.5 × 10⁹/L or lower with a temperature higher than 38 °C or other signs of clinically significant sepsis; SEOM uses a temperature above 38 °C or clinical signs of sepsis with neutrophils below 500/mm³, or below 1000/mm³ before the nadir.
Treatment does not wait for the count. NICE says to offer empiric antibiotics immediately and sets no clock, because its committee found the evidence on timing very low quality; ASCO/IDSA (2018) endorse the first dose within 1 hour of triage, and SEOM (2018) within the first hour of arrival in the emergency department, after cultures. NICE's first choice is piperacillin with tazobactam alone, with no routine aminoglycoside or glycopeptide; SEOM allows any anti-pseudomonal beta-lactam and adds amikacin, preferably with a carbapenem, when severity criteria are met. Bloods include full blood count, renal and liver function with albumin, C-reactive protein, lactate and blood cultures, with a peripheral culture as well as a line culture where there is a central venous device, which stays in.
Within 24 hours a competent clinician scores the risk of septic complications with a validated tool (MASCC; CISNE for stable patients with solid tumours on moderate-intensity chemotherapy in SEOM). A MASCC score of 21 or more marks those who may go home on oral antibiotics; under 21 is high risk and stays on the standard pathway. Under NG253, a high-risk patient who does not respond within 1 hour of any intervention needs a senior decision maker in person and a critical care discussion.
Why: Most episodes start at home between visits, so the person needs to know the signs and whom to ring before they need to.
“Provide patients having anticancer treatment and their carers with written and oral information, both before starting and throughout their anticancer treatment, on:”
Why: The trigger is feeling unwell during treatment, not a number on a thermometer.
“Suspect neutropenic sepsis in patients having anticancer treatment who become unwell.”
Why: People having cancer treatment may be septic without a raised temperature, and steroids or paracetamol can hide one.
“Do not rely on fever or hypothermia alone to rule sepsis either in or out.”
Why: Assessment and the first antibiotic happen in hospital, so any delay at the telephone stage adds to the time before treatment.
“Refer patients with suspected neutropenic sepsis immediately for assessment in secondary or tertiary care.”
Why: Without neutrophils an infection can spread fast, and the antibiotic is the one step that changes the outcome.
“Treat suspected neutropenic sepsis as an acute medical emergency and offer empiric antibiotic therapy immediately.”
Why: The one-hour target is the one most guidelines and audits use; writing down the start time is what lets a team see whether it was met.
“Empirical antibiotic therapy should be initiated within the first hour of arrival at the ED (after sampling for cultures)”
Spanish Society of Medical Oncology (SEOM), Clinical and Translational Oncology 2019 · II, A
Why: NICE's antibiotic recommendation applies to suspected neutropenic sepsis; the count is used afterwards to confirm the diagnosis (CG151 1.4.4.1), not to decide the first dose.
Why: These find the likely source and show how unwell the person is, which decides the next steps.
Why: Cultures taken after the first dose are less likely to grow the germ, but taking them must not push the antibiotic past the hour.
“Two pairs of blood cultures and microbiological specimens, as clinically indicated, should be obtained prior to initiating empirical antibiotic therapy”
Spanish Society of Medical Oncology (SEOM), Clinical and Translational Oncology 2019 · III, A
Why: A second culture from a vein helps show whether the line is the source; taking the line out is not part of the first hour.
“Do not remove central venous access devices as part of the initial empiric management of suspected neutropenic sepsis.”
Why: NICE's analysis found lower mortality and less kidney harm with this single drug than with a carbapenem or with an added aminoglycoside.
“Offer beta lactam monotherapy with piperacillin with tazobactam as initial empiric antibiotic therapy to patients with suspected neutropenic sepsis who need intravenous treatment unless there are patient-specific or local microbiological contraindications.”
Why: NICE limits them to patient-specific or local microbiological reasons, such as a line infection or known resistant organisms.
“Do not offer an aminoglycoside, either as monotherapy or in dual therapy, for the initial empiric treatment of suspected neutropenic sepsis unless there are patient-specific or local microbiological indications.”
Why: NICE found no reason to X-ray every patient; SEOM includes one in the first assessment (see variants).
“Do not perform a chest X-ray unless clinically indicated.”
Why: Failure to respond to antibiotics and fluids in the first hour is the point to bring in intensive care, not after a further wait.
“If a person aged 16 years or over who is at high risk of severe illness or death from sepsis does not respond within 1 hour of any intervention:”
Why: The score separates people who can finish treatment at home from those who need to stay in hospital.
“A healthcare professional with competence in managing complications of anticancer treatment should assess the patient's risk of septic complications within 24 hours of presentation to secondary or tertiary care, basing the risk assessment on presentation features and using a validated risk scoring system.”
Why: In the original validation a score of 21 or more picked out low-risk patients with a positive predictive value of 91 per cent.
“Patients treated with chemotherapy/ICI presenting with febrile neutropenia and a MASCC risk index < 21 are high risk and require standard neutropenic sepsis management.”
Why: The observation period catches people who look well at first but are not; ASCO/IDSA name an oral fluoroquinolone with amoxicillin and clavulanate unless a fluoroquinolone was already being taken as prevention.
“In low-risk patients for whom ambulatory treatment has been decided on, the first dose of antibiotic should be administered via IV within the first hour and the patient should remain in observation at the hospital for at least 4 h”
Spanish Society of Medical Oncology (SEOM), Clinical and Translational Oncology 2019 · III, B
How care is usually carried out, read from the guidelines and standards cited. Your own team's protocol and their judgement come first; this page is for understanding it, not for doing it yourself.
Start empiric intravenous antibiotics on suspicion, without waiting for the neutrophil count. On timing the guidelines differ in wording and in where the clock starts: NICE CG151 says immediately and sets no clock, judging the evidence too weak to name a period while noting the one-hour pathway of the National Cancer Peer Review Programme; ASCO/IDSA (2018) endorse the first dose within 1 hour of triage; SEOM (2018) within the first hour of arrival in the emergency department, after cultures. NICE NG253 times its general sepsis antibiotic from the NEWS2 score at initial assessment but sends neutropenic sepsis back to CG151. On the trigger, NICE confirms the diagnosis at neutrophils of 0.5 × 10⁹/L or lower with a temperature higher than 38 °C or other signs of clinically significant sepsis, and both NICE guidelines warn that people having cancer treatment may not run a temperature; SEOM uses above 38 °C or clinical signs of sepsis with neutrophils below 500/mm³, or below 1000/mm³ before the nadir. On the first drug, NICE recommends piperacillin with tazobactam alone; SEOM allows any anti-pseudomonal beta-lactam (piperacillin with tazobactam, meropenem, imipenem with cilastatin or cefepime) and adds amikacin when severity criteria are met. Risk scoring with MASCC (score of 21 or more is low risk) or, for stable patients with solid tumours, CISNE then decides who can continue at home.
NICE 2012 · NICE (National Collaborating Centre for Cancer) 2012 · NICE 2025 · ASCO and IDSA, Journal of Clinical Oncology 2018 · Spanish Society of Medical Oncology (SEOM), Clinical and Translational Oncology 2019 · MASCC, Supportive Care in Cancer 2026
Where it differs: Sets a local standard of intravenous antibiotics within 60 minutes of presentation, suspects neutropenic sepsis after anticancer treatment in the last 6 weeks with a temperature over 38 °C or under 36 °C, tells staff not to wait for blood count results, and in haematology lets assessed nurses give the first dose of piperacillin with tazobactam under a patient group direction. MASCC scoring is used for solid tumours only.
Evidence: A local policy that cites NICE CG151; it is not graded evidence.
Where it differs: Allows piperacillin with tazobactam, meropenem, imipenem with cilastatin or cefepime as the first beta-lactam, and for high-risk patients meeting severity criteria a beta-lactam, preferably a carbapenem, with amikacin; adds a gram-positive agent for suspected line or skin infection, pneumonia or haemodynamic instability.
Evidence: SEOM grades the beta-lactam choice I, A and the carbapenem with amikacin II, A. NICE advises against a routine aminoglycoside and keeps to piperacillin with tazobactam unless there are patient-specific or local reasons.
Spanish Society of Medical Oncology (SEOM), Clinical and Translational Oncology 2019 · NICE 2012
Where it differs: Includes a chest X-ray in every initial assessment, where NICE advises one only when clinically indicated.
Evidence: SEOM grades its initial evaluation including chest X-ray III, B; NICE makes the opposite recommendation without a grade.
Spanish Society of Medical Oncology (SEOM), Clinical and Translational Oncology 2019 · NICE 2012
Where it differs: Uses the Clinical Index of Stable Febrile Neutropenia (0 low, 1 to 2 intermediate, 3 or more high risk) in people with solid tumours on moderate-intensity chemotherapy who look clinically stable, and never in haematological cancers or lymphoma.
Evidence: SEOM grades CISNE II, B. In the CISNE validation cohort of 1,133 patients the area under the curve was 0.868 for CISNE against 0.721 for MASCC.
Spanish Society of Medical Oncology (SEOM), Clinical and Translational Oncology 2019 · Journal of Clinical Oncology 2015
| Recommendation | Grade, as printed | Source |
|---|---|---|
| Empirical antibiotics within the first hour of arrival in the emergency department, after cultures “Empirical antibiotic therapy should be initiated within the first hour of arrival at the ED (after sampling for cultures)” | II, A | Spanish Society of Medical Oncology (SEOM), Clinical and Translational Oncology 2019 |
| First intravenous antibiotic is an anti-pseudomonal beta-lactam “Initial parenteral antibiotherapy should include a beta-lactam with activity against Pseudomonas spp. (piperacillin/tazobactam, meropenem, imipenem–cilastatin, cefepime)” | I, A | Spanish Society of Medical Oncology (SEOM), Clinical and Translational Oncology 2019 |
| Blood cultures before the first antibiotic “Two pairs of blood cultures and microbiological specimens, as clinically indicated, should be obtained prior to initiating empirical antibiotic therapy” | III, A | Spanish Society of Medical Oncology (SEOM), Clinical and Translational Oncology 2019 |
| Severe cases: beta-lactam, preferably a carbapenem, with amikacin “In high-risk patients meeting criteria for severity, initial parenteral antibiotherapy should include a beta-lactam with activity against Pseudomonas spp. (preferably a carbapenem) in combination with amikacin” | II, A | Spanish Society of Medical Oncology (SEOM), Clinical and Translational Oncology 2019 |
| CISNE score for clinically stable patients with solid tumours on moderate-intensity chemotherapy “The application of the CISNE score is recommended in patients with apparent clinical stability and solid tumors on moderate-intensity chemotherapy” | II, B | Spanish Society of Medical Oncology (SEOM), Clinical and Translational Oncology 2019 |
| Outpatient route: first intravenous dose within the hour and at least 4 hours of observation | III, B | Spanish Society of Medical Oncology (SEOM), Clinical and Translational Oncology 2019 |
| First dose of empirical antibiotic within 1 hour of triage and at least 4 hours of monitoring before discharge “The panel continued to endorse consensus recommendations from the previous version of this guideline that patients with febrile neutropenia receive initial doses of empirical antibacterial therapy within 1 hour of triage and be monitored for ≥ 4 hours before discharge.” | consensus recommendations (ASCO/IDSA Expert Panel) | ASCO and IDSA, Journal of Clinical Oncology 2018 |
| MASCC score of 21 or more is likely to be suitable for outpatient or ambulatory care “The MASCC score is a well-validated score for risk stratification in febrile neutropenia and patients with a score ≥ 21 are likely to be suitable for outpatient or ambulatory emergency care” | A | MASCC, Supportive Care in Cancer 2026 |
| MASCC score under 21 is high risk and needs standard neutropenic sepsis management | A | MASCC, Supportive Care in Cancer 2026 |
| Evidence on how fast antibiotics must be given in suspected neutropenic sepsis “The overall quality of the evidence classified by GRADE was ‘very low’.” | very low (GRADE) | NICE (National Collaborating Centre for Cancer) 2012 |
| Evidence for piperacillin with tazobactam monotherapy on mortality and treatment failure “The overall quality of the evidence as classified by GRADE was ‘moderate’ in addressing mortality and treatment failure, and low or very low in relation to adverse effects.” | moderate (GRADE) | NICE (National Collaborating Centre for Cancer) 2012 |
Shares National Institute for Health and Care Excellence and the tags protocol, acute-oncology.
Shares National Institute for Health and Care Excellence and the tags protocol, acute-oncology.
Shares National Institute for Health and Care Excellence and the tags protocol, acute-oncology.
Shares American Society of Clinical Oncology (ASCO) and the tags protocol, acute-oncology.
Shares American Society of Clinical Oncology (ASCO) and the tags protocol, acute-oncology.
Shares American Society of Clinical Oncology (ASCO) and the tags protocol, acute-oncology.
Shares the tags protocol, acute-oncology.
Shares the tags protocol, acute-oncology.